GENOME COMPANY
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Genome & Company Announces Positive Topline Results from Phase 2 Clinical Trial of Combination of GEN-001 and Bavencio® for the Treatment of Gastric Cancer Poster presented at ASCO GI 2024-01-24 21:00
Positive Results from Interim Analysis of 'GEN-001' Plus avelumab (Bavencio®) Phase II Trial 2023-05-19 21:00
Positive Results from Interim Analysis of 'GEN-001' Plus avelumab (Bavencio®) Phase II Trial 2023-05-19 16:00
Genome and Company announces Clinical Trial Collaboration with MSD to evaluate 'GEN-001' in combination of KEYTRUDA® (pembrolizumab) in phase 2 clinical trial in biliary tract cancer patients 2022-03-04 09:30
Genome and Company signs second clinical trial collaboration and supply agreement (Phase 2) with Merck KGaA, Darmstadt, Germany and Pfizer for immuno-oncology microbiome study 2021-03-09 22:00
Genome & Company and Debiopharm Join Forces To Create New Highly Specific Therapies for Cancer Patients 2021-02-25 07:00
Genome & Company announces first patient dosed in Phase 1/1b study of GEN-001, an immuno-oncology microbiome therapeutic, in combination with avelumab 2020-10-27 21:00
1